UroGen Pharma Ltd. cotiza a 38.28 USD y tiene una capitalización bursátil de $1.9B. En los últimos 12 meses ha facturado $189M con un margen de flujo de caja libre del -148.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.28 | $-0.47 | $-0.53 |
| Estimado | $0.09 | $-0.26 | $-0.48 | $-0.51 |
| Sorpresa | — | -7.7% | +2.1% | -3.9% |
| Métrica | URGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 88.7% | 57.0% | +31.6% |
| Operating Margin | -113.7% | -38.6% | -75.1% |
| Net Margin | -139.8% | -33.6% | -106.3% |
| FCF Margin | -148.2% | -13.9% | -134.4% |
| ROE | — | -40.4% | — |
| ROA | -76.6% | -32.0% | -44.6% |
| Current Ratio | 4.01 | 2.84 | +1.17 |
| Debt / Equity | -1.19 | 0.28 | -1.47 |